Publication | Closed Access

Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

Tumor BiologyAntitumor ActivityMedicinePharmacologyAnti-cancer AgentCancer TreatmentOncologyCell BiologyCancer Research